Ropivacaine extended release (PainReform)

PainReform's Phase 3 clinical trial of PRF-110 for post-surgical pain management in bunionectomy patients did not meet its primary endpoint.

PainReform's PRF-110 demonstrated statistically significant superiority over placebo in reducing pain within the first 48 hours post-bunionectomy, according to initial Phase 3 data.

PainReform's PRF-110 demonstrated statistically significant pain reduction compared to placebo in the first 48 hours post-bunionectomy, suggesting effective early postoperative pain relief.

PainReform's PRF-110, a non-opioid post-surgical pain relief solution, demonstrates compatibility with both non-absorbable and resorbable sutures in human clinical trials.